ClinicalTrials.gg
CompletedNCT01838161INSPIREUpdated May 7, 2019

Improving Adolescent Vaccination in Appalachian Kentucky

An interventional study of Part II and Part III in Adolescent Immunization, sponsored by University of Minnesota. Completed at 2 sites in United States. Open to participants aged 11 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-07.

Sponsored by University of Minnesota · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
597
Allocation
Randomized
Ages
11 Years to 70 Years
Sex
All
01

Study summary

The proposed project develops a community and school-based intervention to enhance understanding of the importance all age-appropriate vaccinations, and uses an innovative, comprehensive approach (Project INSPIRE - Instilling Necessary Sickness Prevention with Immunizations Reaching Everyone) to ensure that all parents of adolescents are advised of all age-appropriate vaccines for sickness prevention. The investigator will develop a novel set of targeted video vignette persuasive informational decision aids (including target population representatives) to enhance lay understanding of recommended adolescent (or catch-up) vaccines. The Investigator will also partner with school districts to develop a replicable social marketing vaccination event program (Project INSPIRE) to encourage parents and teens to publicly vaccinate at community events and during drop-in school nursing clinic hours. The project will test the efficacy of the video-based health education intervention + standard of care to ideal standard of care (social marketing vaccination event program) approaches to immunize adolescents in this region.

Read the detailed description

This is not an interventional study in which subject will be given a investigator drug or device.

Part I of the INSPIRE intervention development will involve formative research interviews conducted with parents of adolescents. Interview questions will focus on reticence to vaccinate children. Participants will be a convenience sample recruited through contacts in local public health departments and community nurses recruited by flyer and the research study coordinators (UK study personnel). Interview sessions will be scheduled in advance and will take approximately 30 minutes.

Part II of the INSPIRE intervention development will be evaluated in a small clinic-based pilot study using the same pre-test/post-test intervention design as in the planned (Part III) trial. For the pilot testing, the investigators will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents. Eligible parents who are coming in for non-acute care appointments will be asked by a research nurse to enroll in a research study. The Investigator will then administer a pretest survey, expose participants (parents) to vignette condition using the iPad in the clinic, and a post-test survey measuring intention to receive appropriate adolescent vaccines for their child as well as perceived message effectiveness (for the vignette). At the conclusion of the study, the research personnel administering the study will refer the adolescent to the clinic staff who will offer adolescent vaccines at the conclusion of the study (and/or a cue to schedule an appointment for the adolescent to visit the clinic) and will be able to examine actual behavior by receiving informed consent (from parents and adolescent) for limited medical record review (to track adolescent receipt of vaccinations). The Investigator will perform this pilot study in one Kentucky River Area District health department clinic with 30 parents. This method has been used to pilot past interventions, and it is expected that this allow us to correct for any problems in either the design of the survey assessment or the intervention. If needed, the investigator can tweak the intervention and re-pilot using the same procedures before the randomized controlled trial. This pilot test will also provide the advantage of assuring us that the intervention procedure can translate to the clinic setting. The Investigator has experience with this translation from our 1-2-3 Pap video intervention which the investigators began in social settings (recruiting people at school and other community events) and moved into the clinic setting for dissemination.

Part III of the INSPIRE project will be evaluated in a site-based group randomized controlled trial design, with individual-level randomization also occurring within the intervention group. Community vaccination clinic and health education sites (staffed by local health department contracted personnel and project nurses) in the intervention and control conditions will be matched on percentage of free/reduced school lunch and relevant demographics. At the end of Year 1, one health site in each pair will be randomized to the enhanced video educational intervention (video vignettes + standard of care social marketing vaccine event) or a standard of care vaccination campaign (standard of care health department vaccine event) comparison group. Individuals in the intervention group randomized condition also will be randomized when recruitment occurs in non-school based locations. Assessments will be conducted using Automated iPad Audio Assisted Interviewing techniques at pretest, immediate post-test, and then medical record review at 1 month and 9 month follow-up points. The medical record review will entail examining the medical record for each adolescent vaccine received by the patient. Thus, the investigators will be able to examine behavior change (i.e., receipt of vaccination) for each of the different vaccine types and their single or multi-dose outcomes.

02

Conditions studied

  • Adolescent Immunization

Keywords

  • adolescents
  • immunizations
03

In context

Lead sponsor

University of Minnesota is the lead sponsor of 1,210 studies on the registry; 194 are open to participants now.

Of its 133 completed or terminated interventional studies of FDA-regulated products, 92 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parents/guardians with legal custody of a minor child
  • Parents of children 11-18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Parents under the age of 18
  • Allergy to vaccinations
  • Parent has made an informed decision not to vaccinate their child
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
597 participants (actual)

Study arms

  • Active comparator
    Part I

    Interview questions will focus on reticence to vaccinate children.

    Behavioral: Part I

  • Experimental
    Part II

    We will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents. * a pretest survey * the video vignette * and a post-test survey measuring intention to receive appropriate adolescent vaccines

    Behavioral: Part II

  • Experimental
    Part III

    * enhanced video educational intervention (video vignettes + standard of care vaccine event) * standard of care vaccination event

    Behavioral: Part III

Interventions

  • BehavioralPart II

    Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.

  • BehavioralPart III

    •video educational

    Also known as: Video Education

  • BehavioralPart I

    Parental Interviews

06

What researchers measure

Primary outcomes

  1. Part I - Parent Interviews

    Interview questions will focus on reticence to vaccinate children. Participants will be a convenience sample recruited through contacts in local public health departments, community nurses and the research study coordinators.

    Time frame: 1 year

Secondary outcomes

  1. Part II - Intention to Vaccinate

    The investigator will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents. The Investigator will then expose parents to vignette condition using the iPad, administer a pretest survey, the video vignette, and a post-test survey measuring intention to receive appropriate adolescent vaccines for their child as well as perceived message effectiveness (for the vignette).

    Time frame: 1 Year

Other outcomes

  1. Part III - Site-based group randomized controlled trial design - Vaccination outcomes

    Community vaccination clinic sites in the intervention and control conditions will be matched on percentage of free/reduced school lunch and relevant demographics. Randomization will occur at the group and individual level. One site in each pair will be randomized to the enhanced video educational intervention condition (within this group individuals will be randomized to video vignettes + standard of care vaccine education or the standard of care vaccine education) or a standard of care (standard of care vaccine education) comparison group. The medical record review will allow us to examine behavior change (i.e., receipt of age-appropriate vaccinations) for each of the different vaccine types and their single or multi-dose outcomes.

    Time frame: 1 year

07

Study locations

2 sites
  • University of Kentucky
    Lexington, Kentucky 40475, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
08

References and documents

Publications

  • Cohen, E. L. and K. J. Head (2014).

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2013
First posted
Apr 23, 2013
Start
Apr 2013
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Last update
May 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01838161
Collaborators
Merck Sharp & Dohme LLC, University of Kentucky
Responsible party
Sponsor
First posted
Apr 23, 2013
Start date
Apr 2013
Primary completion
Jan 2016
Completion
Jan 2016
Last update
May 7, 2019

Study contacts

Elisia Cohen, PhD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion